Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.910
-0.020 (-0.51%)
At close: Jun 18, 2026, 4:00 PM EDT
3.920
+0.010 (0.26%)
After-hours: Jun 18, 2026, 7:48 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $71.43M in the quarter ending March 31, 2026, with 44.82% growth. This brings the company's revenue in the last twelve months to $285.61M, up 34.29% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth.
Revenue (ttm)
$285.61M
Revenue Growth
+34.29%
P/S Ratio
6.11
Revenue / Employee
$292,931
Employees
975
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AnaptysBio | 232.39M |
| Syndax Pharmaceuticals | 217.17M |
| Zymeworks | 81.26M |
| AbCellera Biologics | 79.21M |
| Nurix Therapeutics | 71.78M |
| Recursion Pharmaceuticals | 66.41M |
| Nanobiotix | 38.27M |
| Precigen | 31.60M |
IOVA News
- 1 day ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Iovance Biotherapeutics files automatic mixed securities shelf - TheFly
- 10 days ago - Iovance Biotherapeutics Transcript: AGM 2026 - Transcripts
- 16 days ago - Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Iovance receives Australian approval of Amtagvi for advanced melanoma - TheFly
- 17 days ago - Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia - GlobeNewsWire
- 19 days ago - Iovance gets allowance to proceed from FDA for IOV-5001 IND application - TheFly
- 20 days ago - Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 - GlobeNewsWire